Topic: research and development
Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two research labs in nearby cities.
Skyhawk Therapeutics is teaming up with Takeda to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.
Though biopharmas seem to be using their R&D dollars more effectively, they are only converting 24% of new molecular entities to approved drugs.
Germany's Merck is poised to expand its R&D facilities in China next year.
Bayer is restructuring its pharma R&D and consumer health operations, a long-awaited move it says will refocus assets on core life science businesses.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.
GlaxoSmithKline’s former head of dermatology R&D, David Gordon, has joined Aclaris Therapeutics as its new chief medical officer.
German pharma company Bayer is said to be reviewing its R&D locations, with fears this may lead to the swinging of an ax across some operations.
Curis is bringing on board member Robert Martell, formerly CMO at Tesaro, as a full-time employee in the newly created role to head its R&D.